Trump Administration Eases Access to Unproven Peptides Amid FDA Opposition

The Trump administration has moved to broaden access to unproven peptide drugs, a decision that faced opposition from scientific staffers within the Food and Drug Administration (FDA), according to individuals familiar with the policy's development. The draft policy, released by the Department of Health and Human Services (HHS), would permit specialty pharmacies to offer a group of injectable peptides promoted for various wellness uses.

The measure, which will be open for public comment for two weeks before being finalized, covers peptides such as BPC-157, TB-500, and KPV. Under existing FDA regulations, these substances would be considered illegal drugs as they have not undergone the agency's rigorous review for safety and effectiveness.

Officials at HHS stated that the policy change aims to "advance patient choice and freedom" while also protecting consumers from peptides sourced from unknown or questionable origins. Health Secretary Robert F. Kennedy Jr. has publicly expressed his support for peptides, noting his personal use of BPC-157 to treat a muscle injury.

Lee Rosebush of the American Academy of Peptide Medicine, a group representing peptide prescribers and sellers, described the HHS action as a "huge step for patient and provider medical freedom." Major telehealth providers, such as Hims & Hers, have indicated plans to offer wellness peptides following the policy shift, with market analysts projecting the sector could be worth over $2 billion.

Background on Wellness Peptides

While some peptides naturally occur in the body and are crucial for biological functions, the peptides targeted by this new policy have not received FDA approval for safety or efficacy. Despite this, they are marketed online for a variety of purported medical benefits, including addressing insomnia, anxiety, inflammatory conditions, and migraines.

Critics argue that these unapproved peptides divert individuals from scientifically validated treatments. Dr. Peter Lurie, former FDA official and president of the Center for Science in the Public Interest, stated that the FDA has already approved medications for the conditions these peptides claim to treat, and diversion towards unproven substances could lead to "unnecessary pain and suffering."

Lurie also questioned the timing of the announcement, suggesting it might be politically motivated. A spokesperson for HHS defended the policy, asserting that it provides a "more controlled alternative through licensed US compounders" as a way to combat risks associated with black-market peptides.

This move represents a departure from previous FDA efforts to restrict the availability of unproven wellness products. HHS officials had initially considered a formal regulation to deem certain peptides safe for compounding pharmacies, but FDA staff expressed significant safety concerns, leading to the current approach of directing the FDA not to enforce existing rules against pharmacies that compound these substances.

Concerns Over Regulation and Safety

FDA staffers provided technical assistance on the HHS plan, incorporating safeguards such as requiring pharmacies to source peptide ingredients from FDA-registered facilities and to collect data on side effects. However, Lurie pointed out that the FDA lacks the legal authority to enforce these specific pharmacy requirements. The Alliance for Pharmacy Compounding, representing specialty pharmacies, has called for clarification on the policy's implementation and its interaction with state pharmacy boards.

Historically, decisions regarding the regulation of peptides and compounding pharmacies have been managed by the FDA, particularly after a 2012 meningitis outbreak linked to contaminated compounded injections. This incident heightened the FDA's focus on compounding safety.

While HHS technically holds overarching authority for drug regulations, it is unusual for the department to lead policy drafting in this area, which has traditionally fallen to the FDA's specialized office.

The FDA has previously warned about the safety risks of unproven peptides, including potential allergic reactions, kidney damage, and tumor growth. In 2023, the agency added over a dozen peptides to its list of substances not recommended for compounding. Despite these warnings, an external expert panel, selected by HHS, recently voted to remove restrictions on six of the peptides mentioned in the new policy, citing a lack of proven safety and effectiveness.

The policy is now open for a two-week public comment period before its finalization.